AbbVie(ABBV) - 2025 Q1 - Quarterly Results

Financial Guidance - Full-year 2025 adjusted diluted EPS guidance is projected to be between $11.99 and$12.19, including the impact of Q1 2025 expenses[6] - Q1 2025 adjusted diluted EPS guidance is estimated to be between $2.34 and$2.38, factoring in the acquired IPR&D and milestones expense[6] Expenses and Impact - AbbVie expects acquired IPR&D and milestones expense of $248 million for Q1 2025, impacting GAAP and adjusted non-GAAP diluted EPS by$0.13[5] - The licensing agreement with Gubra for GUB014295 closed after Q1 2025 and is not included in the current guidance[6] Risks and Uncertainties - AbbVie cautions that forward-looking statements are subject to risks and uncertainties that may materially affect actual results[9]